NRX Pharmaceuticals Inc. Warrant (NRXPW)

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United...  States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware. Address: 1201 N. Market Street, Wilmington, DE, United States, 19801  Read more

• Co-Founder, Chief Scientist Officer & Chairman

  Dr. Jonathan C. Javitt M.D., M.P.H.

• Co-Founder, Chief Scientist Officer & Chairman

  Dr. Jonathan C. Javitt M.D., M.P.H.

• Headquarters

  Wilmington, DE

• Website

  https://www.nrxpharma.com